Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,921,001 papers from all fields of science
Search
Sign In
Create Free Account
MKC-1
An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Microtubule Process
R440
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer
S. Yousuf
,
Meiling Duan
,
+8 authors
D. Chatterjee
PLoS ONE
2014
Corpus ID: 9000326
Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine-binding-protein (PEBP) family that modulates the…
Expand
Review
2012
Review
2012
mTOR inhibitors in breast cancer: a systematic review.
F. Zagouri
,
T. Sergentanis
,
D. Chrysikos
,
M. Filipits
,
R. Bartsch
Gynecologic Oncology
2012
Corpus ID: 205796013
2012
2012
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design
A. Tevaarwerk
,
G. Wilding
,
+6 authors
Glenn Liu
Investigational new drugs
2012
Corpus ID: 25559156
SummaryBackground MKC-1 is an oral cell-cycle inhibitor with broad antitumor activity in preclinical models. Clinical studies…
Expand
2012
2012
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
J. Faris
,
J. Arnott
,
+9 authors
E. Kwak
Investigational new drugs
2012
Corpus ID: 23606773
SummaryBackground MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin…
Expand
2009
2009
Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer.
C. Elser
,
H. Hirte
,
+7 authors
A. Oza
Journal of Clinical Oncology
2009
Corpus ID: 12301460
5577 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity in xenograft models of human ovarian and…
Expand
2009
2009
Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
N. Hanna
,
D. Estes
,
+6 authors
T. Hoang
Journal of Clinical Oncology
2009
Corpus ID: 45111305
e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi…
Expand
2008
2008
A phase II study of oral MKC-1 for metastatic breast cancer (MBC)
B. Schneider
,
M. Karwal
,
+6 authors
K. Miller
2008
Corpus ID: 74014467
1046 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines…
Expand
2007
2007
Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T)
L. Sylvester
,
L. Laufman
,
+7 authors
K. Miller
2007
Corpus ID: 68070590
11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity…
Expand
2006
2006
MKC-1 Is a Novel Agent That Induces Cell Cycle Arrest and Disrupts Multiple Survival Pathways in Hematologic Cancers.
T. Denny
,
Xiaoru Chen
,
+7 authors
M. Bray
2006
Corpus ID: 90915188
MKC-1 is a novel, orally active cell cycle inhibitor with in vitro and in vivo activity against a wide range of human solid tumor…
Expand
1999
1999
In vitro characteristics of early epidermal progenitors isolated from keratin 14 (K14)‐deficient mice: Insights into the role of keratin 17 in mouse keratinocytes
T. Troy
,
K. Turksen
Journal of Cellular Physiology
1999
Corpus ID: 20129035
Keratin 14 (K14) is believed to play a pivotal role in the maintenance of epidermal cell shape and contributing to their…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE